Benralizumab, an interleukin-5 receptor _ (IL-5R_)-directed cytolytic monoclonal antibody, induces direct, rapid and almost complete depletion of eosinophils by enhancing antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma.